Prices are closing data as of 2026-11-04, not real-time quotes. HK P/E and P/B multiples come from Eastmoney HK key statistics. Metric definitions: P/E, P/B, ROE.
Want the full AI research report for GRAND PHARMA?
This free page compiles public filings, financial ratios and risk screening. Generate a full research report to add business moat & competition, valuation scenarios, catalysts and bull/bear cases right at this URL.
New users who sign up free and verify their email receive 2 free credits for research reports or professional valuation.
10-Year FinancialsFY2016–2025
Key Multi-Year Facts
- Revenue moved from HK$3.70B in FY2016 to HK$12.28B in FY2025 (9-year CAGR +14.3%).
- Profitable in every fiscal year across 2016–2025.
Latest 5 Fiscal Years
| Fiscal Year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue (HKD B) | 8.60 | 9.56 | 10.5 | 11.6 | 12.3 |
| YoY | 35.3% | 11.2% | 10.1% | 10.6% | 5.5% |
| Net Income (HKD B) | 2.40 | 2.08 | 1.88 | 2.47 | 1.24 |
| YoY | 34.0% | -13.4% | -9.6% | 31.3% | -49.7% |
| Operating Cash Flow (HKD B) | 1.64 | 1.65 | 2.20 | 1.76 | 1.49 |
| ROE | 19.5% | 15.1% | 12.8% | 15.6% | 7.4% |
| Gross Margin | 61.0% | 62.2% | 62.0% | 57.9% | 55.2% |
| Net Margin | 27.9% | 21.7% | 17.9% | 21.2% | 10.1% |
| Debt-to-Assets | 36.2% | 36.5% | 32.2% | 33.9% | 37.5% |
Show all 10 fiscal years
| Fiscal Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (HKD B) | 3.70 | 4.77 | 5.96 | 6.59 | 6.35 | 8.60 | 9.56 | 10.5 | 11.6 | 12.3 |
| YoY | — | 29.1% | 24.9% | 10.6% | -3.6% | 35.3% | 11.2% | 10.1% | 10.6% | 5.5% |
| Net Income (HKD B) | 0.27 | 0.46 | 0.71 | 1.15 | 1.79 | 2.40 | 2.08 | 1.88 | 2.47 | 1.24 |
| YoY | — | 71.2% | 54.7% | 61.5% | 55.8% | 34.0% | -13.4% | -9.6% | 31.3% | -49.7% |
| Operating Cash Flow (HKD B) | 0.69 | 0.60 | 1.23 | 1.17 | 1.23 | 1.64 | 1.65 | 2.20 | 1.76 | 1.49 |
| ROE | 15.8% | 23.4% | 15.1% | 14.8% | 18.3% | 19.5% | 15.1% | 12.8% | 15.6% | 7.4% |
| Gross Margin | 46.9% | 52.0% | 53.1% | 61.3% | 63.5% | 61.0% | 62.2% | 62.0% | 57.9% | 55.2% |
| Net Margin | 7.3% | 9.7% | 12.0% | 17.5% | 28.2% | 27.9% | 21.7% | 17.9% | 21.2% | 10.1% |
| Debt-to-Assets | 72.3% | 69.5% | 44.9% | 38.4% | 33.2% | 36.2% | 36.5% | 32.2% | 33.9% | 37.5% |
Fiscal years follow the period-end calendar year (hover headers for period-end dates). ROE uses average beginning/ending equity. Source: HKEX / Eastmoney financial statements, compiled mechanically without AI. Official filings
Risk ChecklistAs of 2026-11-05
Rules-based screening using HK financial statements and HKEX announcement categories (no AI opinions).
Items Flagged for Review
-
Alert
Short-Term Debt CoverageSolvency
Cash HK$0.62B, short-term debt HK$1.67B (0.37x)
Interim (2026-06-30) · What is this?
- Watch
-
Watch
Profit WarningMaterial Events
-
Watch
Auditor ChangeMaterial Events
An "Alert" or "Watch" item flags a number that merits verification in primary filings, not a sell signal.
Dividends
Trailing 12-month dividend: HK$0.167 per share, or 3.89% yield at closing price; last full fiscal year: HK$0.167 (payout ratio 54.6%).
Figures are gross HKD per share before applicable withholding or Stock Connect dividend taxes.
More data: All research reports · Sector leaders · Market hours & holidays.
Compiled mechanically from public filings and market quotes (data as of 2026-11-05). For informational purposes only, not investment advice.